Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration between 2012 and 2022

Samir Kamat; Benjamin Ungar; Aneesh Agarwal; Joy Wan; Joseph S. Ross; Ravi Gupta

doi:10.1001/jamadermatol.2023.5036

Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration between 2012 and 2022

Samir Kamat, Benjamin Ungar, Aneesh Agarwal, Joy Wan, Joseph S. Ross, Ravi Gupta

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	226-229
Number of pages	4
Journal	JAMA Dermatology
Volume	160
Issue number	2
DOIs	https://doi.org/10.1001/jamadermatol.2023.5036
State	Published - Feb 21 2024

ASJC Scopus subject areas

Dermatology

Access to Document

10.1001/jamadermatol.2023.5036

Cite this

@article{f09e4adee70f43aabf77de9b3f7598bb,

title = "Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration between 2012 and 2022",

author = "Samir Kamat and Benjamin Ungar and Aneesh Agarwal and Joy Wan and Ross, {Joseph S.} and Ravi Gupta",

year = "2024",

month = feb,

day = "21",

doi = "10.1001/jamadermatol.2023.5036",

language = "English (US)",

volume = "160",

pages = "226--229",

journal = "JAMA Dermatology",

issn = "2168-6068",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration between 2012 and 2022

AU - Kamat, Samir

AU - Ungar, Benjamin

AU - Agarwal, Aneesh

AU - Wan, Joy

AU - Ross, Joseph S.

AU - Gupta, Ravi

PY - 2024/2/21

Y1 - 2024/2/21

UR - http://www.scopus.com/inward/record.url?scp=85181039280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85181039280&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2023.5036

DO - 10.1001/jamadermatol.2023.5036

M3 - Letter

C2 - 38117528

AN - SCOPUS:85181039280

SN - 2168-6068

VL - 160

SP - 226

EP - 229

JO - JAMA Dermatology

JF - JAMA Dermatology

IS - 2

ER -

Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration between 2012 and 2022

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this